FibroGen, Inc. — Q1 2024 Form 10-Q
Filing identity: The supplied filing is for FibroGen, Inc. (Nasdaq: FGEN), not Kyntra Bio, Inc. It covers the three months ended March 31, 2024; financial amounts below are in U.S. dollars unless noted.
Business context and reporting period
FibroGen develops and commercializes therapeutics in oncology and anemia. Roxadustat is marketed for chronic kidney disease anemia in China, Europe, Japan and other countries; pamrevlumab and oncology candidates FG-3246, FG-3165 and FG-3175 remain in development. The company reports one operating segment.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Total revenue | $55.9 million | $36.2 million; up 55% |
| Operating costs and expenses | $87.0 million | $112.3 million; down 23% |
| Operating loss | $31.1 million | $76.1 million loss |
| Net loss | $32.9 million | $76.7 million loss |
| Net loss per share, basic and diluted | $0.33 | $0.81 |
| Net cash used in operating activities | $59.3 million | $101.6 million |
Operating loss was approximately 56% of revenue and net loss approximately 59% of revenue. The filing does not present a single overall gross-margin figure; cost of goods sold was $25.8 million. Revenue included $30.5 million of China roxadustat product revenue and a $25.7 million cumulative catch-up adjustment related to the AstraZeneca U.S./rest-of-world agreement termination. Related cost of goods sold was $21.1 million.
At March 31, 2024, cash and cash equivalents were $105.7 million and short-term investments were $71.9 million, totaling $177.6 million. Accounts receivable was $37.1 million; cash, investments and receivables together were $214.7 million. Cash and short-term investments declined from $235.6 million at year-end 2023. Total assets were $365.9 million, total liabilities $552.0 million, and stockholders’ deficit $228.1 million. Accumulated deficit was $1.875 billion.
Debt included a $72.2 million carrying balance on a $75.0 million senior secured term loan, bearing 14% stated interest and maturing May 2026, and a $53.4 million liability related to the sale of future revenues. The company reported compliance with loan covenants, including the requirement to maintain at least $30 million of unrestricted U.S. cash.
Material changes versus the prior comparable period
- Revenue rose 55%, mainly from higher China roxadustat sales and the one-time $25.7 million AstraZeneca termination-related revenue adjustment. China product revenue increased 26% to $30.5 million.
- License revenue fell to zero from $6.0 million, which had included Eluminex milestone revenue in Q1 2023. Development and other revenue declined 77% to $0.9 million as collaboration activity wound down.
- Research and development expense fell 48% to $38.4 million, and selling, general and administrative expense fell 33% to $22.8 million. The company cited reduced clinical-trial activity, workforce reductions and cost controls.
- Operating cash use improved by $42.3 million year over year, but remained substantial. The quarter’s cash decrease was $8.0 million, partly offset by $51.3 million of investing cash inflow, primarily investment maturities.
Outlook, management commentary, risks and unusual items
- Management expects existing cash, investments and receivables to fund anticipated requirements for at least 12 months from issuance of the financial statements, based on its current plan. It also says additional capital may be needed and that assumptions could change; the company expects continuing losses.
- Topline results from the pamrevlumab metastatic pancreatic cancer study were expected in mid-2024; topline results from the Phase 3 LAPIS study in locally advanced pancreatic cancer were expected in Q3 2024. The filing reports that the metastatic study portion was completed in Q1.
- For roxadustat in chemotherapy-induced anemia in China, the company expected an approval decision in the second half of 2024. It reported Q1 China sales volume growth of more than 39% year over year and approximately 47% value share in the stated CKD anemia segment as of February 2024.
- AstraZeneca terminated its non-China roxadustat agreement effective February 25, 2024, except for South Korea, returning rights to FibroGen. FibroGen may owe mid-single-digit royalties on its sales in terminated territories or 35% of revenue if it licenses or sells those rights to a third party. The China collaboration continues. The termination produced the quarter’s $25.7 million revenue adjustment, and related receivables and accrued liabilities were settled in April 2024.
- FibroGen anticipates starting a Phase 2 FG-3246 dose-optimization study in the second half of 2024 and plans to submit an IND for FG-3175 in 2025. Exercising its Fortis acquisition option would require an $80 million payment, with up to $200 million of additional contingent payments; the option’s outcome is not stated as decided.
- Significant exposures include clinical and regulatory uncertainty, dependence on roxadustat collaborations and China operations, possible generic competition in China, funding needs, and supply/manufacturing risks. The filing also describes a $28.5 million securities class-action settlement in principle, expected to be fully recoverable under insurance, with final approval hearing scheduled for May 16, 2024; derivative lawsuits; and an ongoing SEC investigation concerning roxadustat cardiovascular safety data. The company says it is cooperating with the SEC and cannot estimate any potential loss.
- Other commitments include $35.6 million of non-cancelable purchase obligations and $77.7 million of operating lease liabilities. Potential future license milestones of up to approximately $697.9 million are contingent on milestones not yet achieved.
Most important facts for investors to verify
- Confirm the filing entity: the document identifies FibroGen, Inc., not Kyntra Bio, Inc.
- Review the actual pamrevlumab trial results and the China regulatory decision for roxadustat in chemotherapy-induced anemia against the company’s stated timelines.
- Assess recurring revenue and cash burn excluding the AstraZeneca termination-related catch-up adjustment and associated costs.
- Track available liquidity, the $30 million U.S. cash covenant, financing needs, and debt and revenue-interest payment obligations.
- Monitor AstraZeneca rights-transition terms, China roxadustat sales and competitive developments, and the status and potential financial impact of the litigation and SEC investigation.